MCID: GST037
MIFTS: 54

Gastroparesis

Categories: Gastrointestinal diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis 12 52 54 43 15 17 71
Delayed Gastric Emptying 52
Gastroparesis Syndrome 12
Gastroparalysis 12
Gastric Atonia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11914
ICD9CM 34 536.3
MeSH 43 D018589
NCIt 49 C80512
SNOMED-CT 67 196753007
ICD10 32 K31.84
UMLS 71 C0152020

Summaries for Gastroparesis

NIH Rare Diseases : 52 Gastroparesis , or delayed gastric emptying, is a disorder where the food does not move or moves very slowly from the stomach to the small intestine . In gastroparesis, the muscles of the stomach do not work well and digestion takes an abnormally long time. Symptoms of gastroparesis include bloating, nausea, vomiting, weight loss due to poor absorption of nutrients, early fullness while eating meals, heartburn, and abdominal pain. Complications can occur including dehydration, electrolyte abnormalities, blood sugar abnormalities, malnutrition, vitamin deficiencies, stomach ulcers , gastroesophageal reflux , esophagitis , small bowel bacterial overgrowth , and metabolic bone disease. In rare cases, food that is poorly digested can collect in the stomach and form a bezoar, a mass of undigested material that can cause a blockage in the gastrointestinal tract. Gastroparesis is more common in people with diabetes and those who have had recent stomach or intestinal surgery. Other causes include infections, hormonal disorders like hypothyroidism, connective tissue disorders like scleroderma , autoimmune conditions , neuromuscular diseases , psychological conditions, and eating disorders. In some cases, the cause is not known (idiopathic). Diagnosis is made on the basis of a radiographic gastric emptying test . Treatment may include dietary modifications such as adjusting the timing and size of meals, consuming more liquid-based meals, or avoiding foods that are more difficult to digest (such as fatty foods, or foods with too much fiber). Other treatments may include endoscopic procedures to break the bezoar apart and remove it, feeding tubes, surgery, placement of an electrical stimulator , and medication such as metoclopramide , domperidone, erythromycin and cisapride . With proper management many people with gastroparesis can live a relatively normal life. However, others may not tolerate treatment and may experience significant complications, a decreased quality of life, and reduced survival.

MalaCards based summary : Gastroparesis, also known as delayed gastric emptying, is related to idiopathic gastroparesis and stomach disease, and has symptoms including ophthalmoplegia, hemiplegia and signs and symptoms, digestive. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Glucagon and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include testes, small intestine and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Gastroparesis (gastro- from Ancient Greek γαστήρ - gaster, "stomach"; and -paresis, πάρεσις - "partial... more...

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)
# Related Disease Score Top Affiliating Genes
1 idiopathic gastroparesis 32.1 MRC1 HMOX1 GIP GHSR GHRL
2 stomach disease 32.0 SST MLNR MLN GHRL GAST CCK
3 autonomic neuropathy 31.2 MLNR MLN GAST CCK
4 diabetic autonomic neuropathy 31.0 MLNR MLN GAST
5 pylorospasm 31.0 MLNR MLN
6 tardive dyskinesia 30.9 DRD3 DRD2 CYP2D6
7 gastroesophageal reflux 30.6 MLN GHRL GAST DRD2 CCK
8 rumination disorder 30.5 MLNR HTR3A
9 pyloric stenosis 30.5 SST NOS1 MLN GAST
10 peptic ulcer disease 30.5 SST GHRL GAST
11 small cell cancer of the lung 30.2 SST GAST CCK
12 atrophic gastritis 30.2 SST GHRL GAST
13 duodenal ulcer 30.1 SST MLN GAST CCK
14 eating disorder 30.1 GHRL DRD3 DRD2 CCK
15 gastrointestinal system disease 30.1 MLN GHRL GAST CCK
16 cholelithiasis 30.0 SST GAST CCK
17 mucositis 30.0 HTR3A GHRL ABCB1
18 duodenogastric reflux 29.9 SST MLN GAST CCK
19 gallbladder disease 29.9 SST MLN CCK
20 intestinal obstruction 29.9 SST MLNR MLN GHRL ANO1
21 tetrahydrobiopterin deficiency 29.9 TH NOS1
22 irritable bowel syndrome 29.8 SST MLN HTR3A GHRL CCK
23 pain agnosia 29.8 HTR3A CYP2D6 CCK
24 ileus 29.7 SST MLN GHSR GHRL CCK
25 biliary dyskinesia 29.7 SST CCK
26 bulimia nervosa 29.7 HTR3A GHRL DRD2 CCK
27 hyperglycemia 29.5 SST GIP GHRL CCK
28 sexual disorder 29.4 NOS1 HTR3A DRD3 DRD2 CYP3A4 CYP2D6
29 diarrhea 29.3 SST MLN HTR3A GAST CYP3A4 CYP2D6
30 mood disorder 29.2 TH NOS1 HTR3A DRD3 DRD2 DRD1
31 dumping syndrome 29.0 SST MLN GIP GHRL GAST CCK
32 anxiety 28.9 TH HTR3A DRD3 DRD2 CYP3A4 CYP2D6
33 migraine with or without aura 1 28.9 NOS1 HTR3A DRD3 DRD2 DRD1 CYP3A4
34 alcohol dependence 28.9 TH HTR3A GHRL DRD3 DRD2 DRD1
35 diabetes mellitus 28.5 TH SST MLN HMOX1 GIP GHRL
36 constipation 28.4 TH SST NOS1 MLNR MLN HTR3A
37 parkinson disease, late-onset 28.4 TH NOS1 HTR3A HMOX1 DRD3 DRD2
38 diabetes mellitus, noninsulin-dependent 27.7 TH SST HMOX1 GIP GHRL DRD2
39 brittle diabetes 11.6
40 galactorrhea 10.6 DRD2 CYP2D6
41 gastrointestinal neuroendocrine benign tumor 10.5 SST GAST
42 non-functioning pancreatic endocrine tumor 10.5 SST GAST
43 rectum neuroendocrine neoplasm 10.5 SST GAST
44 hypertrophy of tongue papillae 10.5 CYP3A4 CYP2D6
45 early-onset schizophrenia 10.5 DRD2 DRD1
46 gastric neuroendocrine neoplasm 10.5 SST GAST
47 polysubstance abuse 10.5 DRD3 DRD2
48 duodenal gastrinoma 10.5 SST GAST
49 appendix lymphoma 10.5 SST GAST
50 glucagonoma 10.5 SST GAST

Graphical network of the top 20 diseases related to Gastroparesis:



Diseases related to Gastroparesis

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:


ophthalmoplegia, hemiplegia, signs and symptoms, digestive, lassitude, persistent vomiting

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.89 SST
2 Decreased viability GR00249-S 9.89 ABCB1 ANO1 GHRL GHSR MLN NOS1
3 Decreased viability GR00381-A-1 9.89 CYP2D6 GHSR HTR3A MLN MLNR
4 Decreased viability GR00381-A-2 9.89 GHSR
5 Decreased viability GR00381-A-3 9.89 GHSR HTR3A MLN
6 Decreased viability GR00386-A-1 9.89 CCK DRD1 MLN
7 Decreased viability GR00402-S-2 9.89 ABCB1 CYP2D6 GHSR HTR3A MLN

MGI Mouse Phenotypes related to Gastroparesis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 ABCB1 ANO1 DRD1 DRD2 DRD3 GHRL
2 digestive/alimentary MP:0005381 10.11 ABCB1 ANO1 DRD1 DRD2 DRD3 GAST
3 homeostasis/metabolism MP:0005376 10.06 ABCB1 ANO1 CCK DRD1 DRD2 DRD3
4 growth/size/body region MP:0005378 10.03 ABCB1 ANO1 DRD1 DRD2 DRD3 GHSR
5 adipose tissue MP:0005375 9.98 DRD1 DRD2 DRD3 GHRL GHSR HMOX1
6 endocrine/exocrine gland MP:0005379 9.97 ABCB1 CCK DRD2 GAST GHRL HMOX1
7 no phenotypic analysis MP:0003012 9.5 ABCB1 CCK DRD2 GHSR NOS1 SST
8 renal/urinary system MP:0005367 9.17 ANO1 CCK DRD2 DRD3 HMOX1 HTR3A

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glucagon Approved Phase 4 16941-32-5
2
Levodopa Approved Phase 4 59-92-7 6047
3
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
6
Carbidopa Approved Phase 4 28860-95-9 34359
7
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
8
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
9
Linaclotide Approved Phase 4 851199-59-2 65351
10
Ticagrelor Approved Phase 4 274693-27-5 9871419
11
Cangrelor Approved Phase 4 163706-06-7 9854012
12
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
13
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
14
Haloperidol Approved Phase 4 52-86-8 3559
15
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
16 Mosapride Investigational Phase 4 112885-41-3
17 Pharmaceutical Solutions Phase 4
18 Dihydroxyphenylalanine Phase 4
19 Proton Pump Inhibitors Phase 4
20 Dopamine agonists Phase 4
21 Emetics Phase 4
22 Antiparkinson Agents Phase 4
23 Adjuvants, Immunologic Phase 4
24 Carbidopa, levodopa drug combination Phase 4
25 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
26 Laxatives Phase 4
27 Cathartics Phase 4
28 Polyethylene glycol 3350 Phase 4
29 Purinergic P2Y Receptor Antagonists Phase 4
30 Platelet Aggregation Inhibitors Phase 4
31 abobotulinumtoxinA Phase 4
32 Cholinergic Agents Phase 4
33 Botulinum Toxins, Type A Phase 4
34 Botulinum Toxins Phase 4
35 Dopamine Agents Phase 4
36 Dopamine Antagonists Phase 4
37 Antiemetics Phase 4
38 Gastrointestinal Agents Phase 4
39 Neurotransmitter Agents Phase 4
40 Antacids Phase 4
41 Anti-Ulcer Agents Phase 4
42 Serotonin Receptor Agonists Phase 4
43 Psychotropic Drugs Phase 4
44 Antipsychotic Agents Phase 4
45 Opiate Alkaloids Phase 4
46 Haloperidol decanoate Phase 4
47
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
48
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
49
Prucalopride Approved Phase 2, Phase 3 179474-81-8
50
Erythromycin Approved, Investigational, Vet_approved Phase 2, Phase 3 114-07-8 12560 441411

Interventional clinical trials:

(show top 50) (show all 349)
# Name Status NCT ID Phase Drugs
1 Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying Unknown status NCT02510976 Phase 4 prucalopride;placebo
2 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
3 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
4 Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Unknown status NCT02264587 Phase 4 Mosapride;domperidone
5 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis Completed NCT00492622 Phase 4 Immediate-release omeprazole;Delayed-release omeprazole
6 Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia Completed NCT00951431 Phase 4 Esomeprazole;Placebo
7 A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
8 Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy: a Randomized Control Trial. Completed NCT03800745 Phase 4 Colace 100Mg Capsule;Miralax
9 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
10 A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding Completed NCT01654770 Phase 4
11 PEG-Electrolyte Solution (FORTRANS®) With Mentholyptus Drops (Halls®) Versus Reduced Volume Ascorbic Acid Supplemented PEG-Electrolyte (MoviPrep®) in Colonoscopy Preparation: A Randomised Controlled Study Completed NCT01788709 Phase 4
12 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Recruiting NCT01642875 Phase 4
13 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit Recruiting NCT04210427 Phase 4 Polyethylene Glycol 3350
14 Platelet Inhibition With Cangrelor in Comatose Survivors of Out-of-hospital Cardiac Arrest Undergoing Primary Percutaneous Coronary Intervention Recruiting NCT04005729 Phase 4 Cangrelor 50 MG
15 Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy Enrolling by invitation NCT03701919 Phase 4 Botulinum toxin pyloroplasty;Normal saline pyloric injection
16 Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
17 An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms Terminated NCT00390975 Phase 4 Tegaserod
18 Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
19 Enterra Therapy Gastric Stimulation System Terminated NCT00556166 Phase 4
20 Haloperidol vs Conventional Therapy for Gastroparesis Terminated NCT02057549 Phase 4 Haloperidol;Conventional Therapy
21 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
22 Prospective Randomized Double-blind Study of Incisional Local Anesthesia in Laparoscopic Surgery (Ketorolac Versus Normal Saline) Withdrawn NCT01374828 Phase 4 Ketolorac
23 A Randomized Controlled Trial of Gastric Meal With and Without Prior Jejunal Feeding on GI Symptoms and Response in Patients With Diabetic Gastro-enteropathy, Diabetic Controls and Healthy Volunteers Withdrawn NCT00944593 Phase 4
24 Comparison Between Antecolic and Retrocolic Gastrointestinal Reconstruction in Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Controlled Multicenter Trial Unknown status NCT01460550 Phase 3
25 Role of Routine Nasogastric Decompression After Subtotal Gastrectomy Unknown status NCT00164918 Phase 3
26 Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3 Sancuso®
27 Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy Unknown status NCT02927886 Phase 3
28 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
29 Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
30 Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
31 Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
32 Phase III Study for the Significance of Nasogastric Decompression Tube After Curative Distal Gastrectomy for Gastric Cancer Patients Completed NCT00738478 Phase 3
33 Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG) Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
34 Sellick Maneuver Evaluation in Rapid Sequence Induction of General Anesthesia Non Inferiority Trial Completed NCT02080754 Phase 3
35 Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial Completed NCT02031081 Phase 2, Phase 3 Prucalopride;Placebo
36 Magnetic Resonance (MR) Evaluation of the Effect of Erythromycin Upon Gastric and Small Bowel Motility Completed NCT01379183 Phase 2, Phase 3 Erythromycin;Placebo
37 A Randomized, Prospective Tiral on Efficacy and Tolerability of Low-volume Bowel Preparation Methods for Colonoscopy Completed NCT02250196 Phase 3 PEG-Asc;SPMC 2
38 Effects of the Abbreviation of Preoperative Fasting With Carbohydrates and Hydrolized Proteins on the Inflammatory Response and Insulin Resistance After Major Abdominal Operations Completed NCT01563965 Phase 3
39 Comparison of a Split Dose Bowel Preparation With 2-L Polyethylene Glycol Plus Ascorbic Acid and 1-L Polyethylene Glycol Plus Ascorbic Acid and Bisacodyl Prior to Colonoscopy Completed NCT02980562 Phase 3 Polyethylene Glycols;Bisacodyl
40 Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation Completed NCT03074448 Phase 3 Sodium Picosulfate
41 VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis Recruiting NCT04028492 Phase 3 Tradipitant;Placebo
42 Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy to Prevent Postoperative Pancreatic Fistula Recruiting NCT03419676 Phase 3
43 Treatment Protocol for the Compassionate Use of Domperidone Recruiting NCT01696734 Phase 3 Domperidone
44 Does the Strengthening of the Pancreas in Distal Pancreatectomy Using Endo GIA Reload Reinforced Reduce the Occurrence of Pancreatic Fistula? Multicenter Randomized Prospective Open Study Recruiting NCT03030170 Phase 3
45 A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Active, not recruiting NCT03383146 Phase 3 Relamorelin;Placebo
46 A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Active, not recruiting NCT03426345 Phase 3 Relamorelin;Placebo
47 A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Active, not recruiting NCT03285308 Phase 3 Relamorelin;Placebo
48 Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis Active, not recruiting NCT03786380 Phase 3 Relamorelin 10 μg
49 A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Enrolling by invitation NCT03420781 Phase 3 Relamorelin;Placebo
50 A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis. Suspended NCT00470795 Phase 3

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisapride
Metoclopramide
Metoclopramide Hydrochloride

Cochrane evidence based reviews: gastroparesis

Genetic Tests for Gastroparesis

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

40
Testes, Small Intestine, Lung, Colon, Bone, Smooth Muscle, Liver

Publications for Gastroparesis

Articles related to Gastroparesis:

(show top 50) (show all 2550)
# Title Authors PMID Year
1
Gastroparesis: Quality of Life and Health Care Utilization. 61 52
27775961 2018
2
Psychological controversies in gastroparesis: A systematic review. 52 61
28275310 2017
3
Gastroparesis: A Review of Current Diagnosis and Treatment Options. 61 52
25874755 2015
4
Gastroparesis: approach, diagnostic evaluation, and management. 61 52
21329779 2011
5
Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying. 61 54
19082715 2009
6
Postprandial secretion of ghrelin in hemodialysis patients with and without diabetic nephropathy. 54 61
19776684 2009
7
Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. 54 61
19434096 2009
8
Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. 54 61
19298585 2009
9
Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. 54 61
19210631 2009
10
No ghrelin response to oral glucose in diabetes mellitus with gastroparesis. 61 54
18946177 2009
11
Application of ghrelin to gastrointestinal diseases. 54 61
18821473 2008
12
Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys. 54 61
17934842 2008
13
Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. 61 54
17894654 2007
14
Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. 61 54
17011824 2006
15
Ghrelin stimulates gastric emptying and hunger in normal-weight humans. 61 54
16772353 2006
16
Abnormal ghrelin and pancreatic polypeptide responses in gastroparesis. 61 54
16868831 2006
17
Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. 61 54
16426704 2006
18
[The effects of enteral nutrition vs parenteral nutrition on gastric motility and gastroenteric hormones after subtotal gastrectomy: a perspective randomized compared clinical trial]. 54 61
16836917 2006
19
Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. 61 54
16492694 2006
20
Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. 54 61
16085693 2005
21
Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. 61 54
16225494 2005
22
Novel approaches to the treatment of nausea and vomiting. 61 54
10697661 1999
23
Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. 54 61
8299441 1993
24
Erythromycin, motilin, and gastroparesis. 61 54
1464218 1992
25
Enhanced recovery outcomes following per-oral pyloromyotomy (POP): a comparison of safety and cost with same-day discharge versus inpatient recovery. 61
31482346 2020
26
Functional restoration of ex vivo model of pylorus: Co-injection of neural progenitor cells and interstitial cells of Cajal. 61
32181603 2020
27
Pathophysiology, Aetiology and Treatment of Gastroparesis. 61
32350720 2020
28
Peroral Pyloromytomy is Effective and Safe for Postsurgical Gastroparesis. 61
32166555 2020
29
Severe Gastroparesis After Ablation for Atrial Fibrillation. 61
32550092 2020
30
Pyloroplasty and the risk of Barrett's esophagus in patients with gastroparesis. 61
32556104 2020
31
Temporary percutaneous radiologic gastrojejunostomy with single gastropexy. 61
32517532 2020
32
Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. 61
32375192 2020
33
Role of endoscopic functional luminal imaging probe in predicting the outcome of gastric peroral endoscopic pyloromyotomy (with video). 61
32035074 2020
34
The High-Resolution Three-Dimensional Magnetic Detector System 3D-Magma Accurately Measures Gastric and Small Bowel Motility in People with Type 2 Diabetes with Neuropathy. 61
32557505 2020
35
Gastrointestinal symptoms and cardiac vagal tone in type 1 diabetes correlates with gut transit times and motility index. 61
32573076 2020
36
FOXF2 acts as a crucial molecule in tumours and embryonic development. 61
32503970 2020
37
Proximal and Distal Gastric Retention Patterns in Gastroparesis and the Impact of Gastric Per-Oral Endoscopic Myotomy: A Retrospective Analysis Using Gastric Emptying Scintigraphy. 61
31811069 2020
38
Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. 61
32301137 2020
39
One-year results of per-oral pyloromyotomy for refractory gastroparesis: a multicenter study. 61
32575130 2020
40
Impact of gastric per-oral endoscopic myotomy on static and dynamic pyloric function in gastroparesis patients. 61
32542920 2020
41
Treating the pylorus in gastroparesis: The new riddle wrapped in the ultimate enigma? 61
32439098 2020
42
Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. 61
32493829 2020
43
Correction to: Pathophysiology of Gastroparesis Syndromes Includes Anatomic and Physiologic Abnormalities. 61
32514641 2020
44
Gastric Peroral Endoscopic Myotomy (GPOEM): a Helpful Tool for Post Laparoscopic Sleeve Gastrectomy Gastroparesis. 61
32524525 2020
45
Pyloric distensibility measurement after gastric surgery: Which surgeries are associated with pylorospasm? 61
31916346 2020
46
Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial. 61
32390563 2020
47
Therapies for diabetic gastroparesis: A protocol for a systematic review and network meta-analysis. 61
32481350 2020
48
Reflux Symptoms in Gastroparesis: Correlation With Gastroparesis Symptoms, Gastric Emptying, and Esophageal Function Testing. 61
30762609 2020
49
Minimally invasive Roux-en-Y reconstruction as a salvage operation after failed nissen fundoplication. 61
31346753 2020
50
Atrial fibrillation ablation-induced gastroparesis: A case report and literature review. 61
32461887 2020

Variations for Gastroparesis

Expression for Gastroparesis

Search GEO for disease gene expression data for Gastroparesis.

Pathways for Gastroparesis

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 SST MLNR MLN GIP GHSR GHRL
2
Show member pathways
12.58 TH NOS1 DRD3 DRD2 DRD1
3 12.18 NOS1 DRD3 DRD2 DRD1
5 11.97 SST GIP GHSR GHRL DRD2 DRD1
6
Show member pathways
11.82 DRD3 DRD2 DRD1
7
Show member pathways
11.78 CYP3A4 CYP2D6 ABCB1
8
Show member pathways
11.74 TH DRD3 DRD2
9
Show member pathways
11.59 CYP3A4 CYP2D6 ABCB1
10
Show member pathways
11.48 CYP3A4 CYP2D6 ABCB1
11
Show member pathways
11.35 CYP3A4 CYP2D6 ABCB1
12
Show member pathways
11.15 CYP3A4 CYP2D6 ABCB1
13
Show member pathways
11.11 CYP3A4 CYP2D6 ABCB1
14 10.84 CYP3A4 ABCB1
15 10.76 CYP3A4 ABCB1
16 10.75 CYP2D6 ABCB1
17 10.74 CYP3A4 ABCB1
18
Show member pathways
10.64 HTR3A CYP3A4 CYP2D6
19
Show member pathways
10.62 TH DRD3 DRD2 DRD1
20 10.55 CYP3A4 ABCB1
21 10.32 GAST CCK
22 10.23 TH GHSR GHRL DRD2

GO Terms for Gastroparesis

Cellular components related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.88 SST NOS1 HTR3A DRD3 DRD2 DRD1
2 neuronal cell body GO:0043025 9.77 TH SST HTR3A GIP CCK
3 cell GO:0005623 9.7 TH NOS1 HMOX1 GHRL DRD3 DRD2
4 axon GO:0030424 9.65 TH HTR3A GHRL DRD2 CCK
5 GABA-ergic synapse GO:0098982 9.61 DRD3 DRD2 DRD1
6 integral component of presynaptic membrane GO:0099056 9.5 HTR3A DRD2 DRD1
7 dopaminergic synapse GO:0098691 9.46 DRD3 DRD2
8 integral component of postsynaptic membrane GO:0099055 9.13 HTR3A DRD2 DRD1
9 glutamatergic synapse GO:0098978 9.1 HTR3A GHSR GHRL DRD3 DRD2 DRD1

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 MLNR HTR3A GIP GHSR GHRL GAST
2 cell-cell signaling GO:0007267 10.03 SST DRD3 DRD2 DRD1
3 response to hypoxia GO:0001666 9.98 TH NOS1 HMOX1 DRD2
4 response to ethanol GO:0045471 9.9 TH HTR3A DRD3 DRD2
5 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.89 DRD3 DRD2 DRD1
6 cellular response to growth factor stimulus GO:0071363 9.89 TH NOS1 HTR3A
7 response to nutrient levels GO:0031667 9.88 TH GIP GHRL
8 learning GO:0007612 9.88 TH DRD3 DRD1
9 excitatory postsynaptic potential GO:0060079 9.87 HTR3A GHRL DRD2
10 response to hormone GO:0009725 9.87 NOS1 GHSR GHRL
11 locomotory behavior GO:0007626 9.86 TH DRD3 DRD2 DRD1
12 response to nicotine GO:0035094 9.85 TH HMOX1 DRD2
13 memory GO:0007613 9.84 TH GIP DRD1 CCK
14 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.83 DRD3 DRD2 DRD1
15 positive regulation of multicellular organism growth GO:0040018 9.83 GHSR GHRL DRD2
16 negative regulation of insulin secretion GO:0046676 9.78 GHSR GHRL DRD2
17 negative regulation of blood pressure GO:0045776 9.77 NOS1 DRD3 DRD2
18 negative regulation of tumor necrosis factor secretion GO:1904468 9.75 GHSR GHRL
19 negative regulation of voltage-gated calcium channel activity GO:1901386 9.75 DRD3 DRD2
20 exogenous drug catabolic process GO:0042738 9.75 NOS1 CYP3A4 CYP2D6
21 oxidative demethylation GO:0070989 9.74 CYP3A4 CYP2D6
22 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.74 DRD3 DRD2
23 behavioral response to ethanol GO:0048149 9.74 DRD3 DRD2
24 neurotransmitter biosynthetic process GO:0042136 9.74 TH NOS1
25 positive regulation of renal sodium excretion GO:0035815 9.74 DRD3 DRD2
26 response to acidic pH GO:0010447 9.74 SST GIP
27 grooming behavior GO:0007625 9.74 DRD2 DRD1
28 G protein-coupled receptor internalization GO:0002031 9.73 DRD3 DRD2
29 striatum development GO:0021756 9.73 DRD2 DRD1
30 positive regulation of growth GO:0045927 9.73 GHSR GHRL
31 adult feeding behavior GO:0008343 9.73 GHSR GHRL
32 regulation of potassium ion transport GO:0043266 9.73 DRD3 DRD2
33 visual learning GO:0008542 9.73 DRD3 DRD2 DRD1 CCK
34 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.72 GHSR GHRL
35 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.72 DRD3 DRD1
36 positive regulation of growth hormone secretion GO:0060124 9.72 GHRL DRD2
37 negative regulation of appetite GO:0032099 9.72 GHSR CCK
38 peristalsis GO:0030432 9.72 DRD2 DRD1
39 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.72 DRD3 DRD2 DRD1
40 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD3 DRD2
41 hyaloid vascular plexus regression GO:1990384 9.7 TH DRD2
42 mating behavior GO:0007617 9.7 TH DRD1
43 heterocycle metabolic process GO:0046483 9.7 CYP3A4 CYP2D6
44 dopamine receptor signaling pathway GO:0007212 9.7 DRD3 DRD2 DRD1
45 response to drug GO:0042493 9.7 TH SST GIP DRD3 DRD2 DRD1
46 drug catabolic process GO:0042737 9.69 CYP3A4 CYP2D6
47 growth hormone secretion GO:0030252 9.69 GHSR GHRL
48 behavioral response to cocaine GO:0048148 9.69 DRD3 DRD2 DRD1
49 cerebral cortex GABAergic interneuron migration GO:0021853 9.68 DRD2 DRD1
50 monoterpenoid metabolic process GO:0016098 9.68 CYP3A4 CYP2D6

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.89 TH NOS1 HMOX1 CYP3A4 CYP2D6
2 monooxygenase activity GO:0004497 9.63 TH CYP3A4 CYP2D6
3 heme binding GO:0020037 9.62 NOS1 HMOX1 CYP3A4 CYP2D6
4 drug binding GO:0008144 9.61 DRD3 DRD2 CYP2D6
5 hormone binding GO:0042562 9.48 MLNR GHSR
6 adrenergic receptor activity GO:0004935 9.43 DRD3 DRD2 DRD1
7 hormone activity GO:0005179 9.43 SST MLN GIP GHRL GAST CCK
8 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD3 DRD2
9 tetrahydrobiopterin binding GO:0034617 9.37 TH NOS1
10 dopamine neurotransmitter receptor activity GO:0004952 9.33 DRD3 DRD2 DRD1
11 dopamine binding GO:0035240 8.92 TH DRD3 DRD2 DRD1

Sources for Gastroparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....